Want to see EXEL full AI Analyst Report?
EXEL Stock Chart & Stats
$55.37
-$0.28(-0.50%)
At close: 4:00 PM EDT
$55.37
-$0.28(-0.50%)
Day’s Range― - ―
52-Week Range$33.76 - $57.57
Previous CloseN/A
Volume1.84M
Average Volume (3M)2.53M
Market Cap
$14.20B
Enterprise Value$11.12K
Total Cash (Recent Filing)$777.21M
Total Debt (Recent Filing)$169.54M
Price to Earnings (P/E)18.1
Beta0.89
Next Earnings
Aug 05, 2026EPS Estimate
0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.12
Shares Outstanding251,355,090
10 Day Avg. Volume2,048,214
30 Day Avg. Volume2,530,490
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)5.48
Price to Sales (P/S)5.10
P/FCF Ratio14.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$51.64Price Target Upside-6.74% Downside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)3.5
Revenue Forecast (FY)$2.60B
Bulls Say, Bears Say
Bulls Say
Profitability & Cash GenerationExtremely high margins and very strong cash conversion (FCF ~99% of net income, OCF well above net income) provide durable internal funding for R&D, trials, and capital returns without near-term financing. This underpins operational resilience and strategic optionality over the next 2–6 months.
Commercial Franchise StrengthSustained share gains and double-digit TRx growth indicate durable product adoption and growing first-line footprint. A large, expanding revenue base from cabozantinib supports predictable near-term cash flow and funds pipeline programs while reducing execution dependence on single upcoming events.
Balance Sheet Strength & BuybacksA strong cash position plus aggressive, executed buybacks reflect free-cash-flow confidence and provide shareholder-aligned capital allocation flexibility. Low reliance on debt combined with ample liquidity supports continued investment in pivotal trials and strategic maneuvers over the medium term.
Bears Say
Rising Gross-to-Net PressureHigher discounts, 340B volume, Medicare Part D rebates and increased co-pay support reduce realized revenue per unit. If structural, these deductions can erode net top-line and margin sustainability, constraining reinvestment capacity and making revenue less resilient to future pricing or reimbursement shifts.
Dependence On Pivotal ReadoutsA material portion of future growth hinges on several timing-sensitive pivotal trials and regulatory decisions (including an NDA under review). Delays, immature data, or negative outcomes would materially affect long-term revenue trajectory and product diversification over the coming months.
Shrinking Equity/Asset BaseDeclining equity and assets reduce the balance-sheet cushion and mean ROE improvements partly reflect a smaller equity base. This diminution limits downside absorption and could elevate financial risk if commercial or clinical setbacks occur, reducing long-term balance-sheet durability.
Exelixis News
EXEL FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $33.76 and its highest was $57.57 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $14.20B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Aug 05, 2026 which is in 6 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on May 05, 2026. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.762 by $0.108.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Overvalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.85.
How many shares outstanding does Exelixis have?
Exelixis has 251,355,090 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.87 in its last earnings report, beating expectations of $0.762. Following the earnings report the stock price went up 9.635%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in EXEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exelixis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$51.64 (-6.74% Downside)
$51.64 (-6.74% Downside)
Blogger Sentiment
Bullish
EXEL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.59%
Trailing 12-Months
Company Description
Exelixis
Exelixis, Inc. (EXEL) is a biotechnology company focused on discovering, developing, and commercializing medicines, primarily in oncology. The company’s core products are small-molecule therapeutics, including its marketed cancer therapy cabozantinib (sold as CABOMETYX and COMETRIQ), and it also advances additional oncology candidates through clinical development.
EXEL Company Deck
EXEL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for CABOMETYX (double-digit global growth, notable TRx and market share gains), solid profitability and cash position, active share repurchases, and substantial advancement of ZANZA with one positive pivotal result (20% OS risk reduction in STELLAR-303 ITT) and multiple ongoing pivotal trials across tumor types. Offsetting these positives were increased gross-to-net deductions (30.2%), a materially higher tax provision, reliance on several upcoming readouts (some immature or timing‑sensitive), and broader development complexity highlighted by a competitive miss in a related triplet program. On balance, operational and commercial strengths and a broad, advancing pipeline materially outweigh the near-term execution and regulatory uncertainties.View all EXEL earnings summariesEXEL Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
EXEL Stock 12 Month Forecast
Average Price Target
$51.64
▼(-6.74% Downside)
Technical Analysis
Ownership Overview
3.52% Insiders
26.04% Mutual Funds
3.02% Other Institutional Investors
38.51% Public Companies and
Individual Investors